Synergistically targeting master regulators of cancer
About Us
Edgewood Oncology is a clinical-stage biotechnology company that was founded to deliver on the promise of BTX-A51 for patients with the greatest unmet medical needs.
Our Science
BTX-A51, a novel small molecule, multi-kinase inhibitor, synergistically co-targets master regulators of cancer to activate programmed cell death, and has demonstrated promising clinical activity with a favorable safety profile.
Our Pipeline
BTX-A51 holds promise in hematologic malignancies and genetically-defined solid tumors, including GATA3-mutant breast cancer, which are the focus of ongoing clinical programs.
